The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy.
暂无分享,去创建一个
[1] P. Harari,et al. The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy. , 2015, Annals of translational medicine.
[2] K. Ang,et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] V. Budach,et al. HPV in , 2014 .
[4] P. Lambert,et al. Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] P. Harari,et al. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Sue S Yom,et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] K. Ang,et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Harari,et al. Is radiation dose reduction the right answer for HPV-positive head and neck cancer? , 2014, Oral oncology.
[9] Menggang Yu,et al. Prevalence of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma in the United States Across Time , 2014, Chemical research in toxicology.
[10] A. Sablina,et al. p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors. , 2014, Cancer research.
[11] J. Overgaard,et al. Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[12] P. Harari,et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. , 2013, Cancer research.
[13] Annie Bruns,et al. Radiation‐induced loss of cell surface CD47 enhances immune‐mediated clearance of human papillomavirus‐positive cancer , 2013, International journal of cancer.
[14] T. Grob,et al. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[15] J. Taube,et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. , 2013, Cancer research.
[16] R. Fisher,et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] K. Ang,et al. Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.
[18] Anjali K. Gupta,et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. , 2009, Archives of otolaryngology--head & neck surgery.
[19] A. Cmelak,et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.